Journal of Infectious Diseases & Therapy
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Nanoparticles from antigenic proteins are highly immunogenic because of the novel quality brought from their particulate
structures. We developed a two-step procedure to generate protein nanoparticles (nanoclusters) from recombinant
trimeric structure-stabilized H7N9 HA (stHA). These nanoclusters have an average diameter of 273.6 nm with a similar Zeta
potential to the soluble protein, demonstrating their comparable solution stability. In a dendritic cell culture, these nanoclusters
were reactive to upregulate the CD86 expression and stimulate the production of TNF-α. To evaluate the immunogenicity
of the nanoclusters, mice were immunized with either intramuscular (i.m.) or intranasal (i.n.) route. We found that these
nanoclusters induced extremely high levels of serum IgG with high neutralization activity as well by i.m route. One i.m.
immunization with 10μg of the nanoclusters provided complete protection against a 10 LD50 live H7N9 virus challenge
with slight bodyweight loss decreases. Two immunizations with either i.m. or i.n. route protected immunized mice against
virus challenges without any disease symptoms. Systemic antibody responses were found to be durable up to six month: IgG
levels were not significantly different in the first three months but dropped in six months. However, the neutralization activity
and hemagglutination inhibition (HAI) titers were not dropped significantly, demonstrating the durability of the protective
antibodies. Because of the high immunogenicity and time-efficient egg-independent production (a few weeks not several
months), stHA nanoclusters have potentials to be developed into a new generation of influenza vaccines, particularly for
fighting an emerging influenza pandemic.
Bao-Zhong Wang has completed his PhD in the year of 2003 from Shanghai Institute of Biochemistry, Chinese Academy of Sciences, Shanghai, China. He is an Assistant Professor in the Department of Microbiology and Immunology, Emory University School of Medicine. He has published more than 35 peer viewed papers.